Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
IDEX’s story today is about whether you believe its pivot toward higher value niches like data centers, semiconductors, and space and defense can support resilient earnings. The latest quarter’s stronger orders and raised guidance support that near term catalyst, while tariff exposure and sector specific softness remain important risks that this update does not eliminate.
The most relevant recent announcement here is IDEX’s report of more than US$1 billion in organic orders, including 47% organic order growth in its Health & Science Technologies segment. That order momentum, particularly tied to data center liquid cooling and semiconductor applications, sits right at the heart of the current bullish narrative but also increases reliance on a handful of fast evolving end markets.
Yet even with these strong orders, investors should be aware that tariff related cost pressures could still...
Read the full narrative on IDEX (it's free!)
IDEX's narrative projects $4.3 billion revenue and $767.8 million earnings by 2029. This requires 6.6% yearly revenue growth and about a $248 million earnings increase from $519.5 million today.
Uncover how IDEX's forecasts yield a $248.00 fair value, a 8% upside to its current price.
Three Simply Wall St Community fair value estimates for IDEX range from about US$180 to US$278 per share, underscoring how far apart individual views can be. When you combine that spread with IDEX’s growing exposure to data center and semiconductor orders, it underlines why checking several independent perspectives on the company’s prospects can be useful.
Explore 3 other fair value estimates on IDEX - why the stock might be worth as much as 21% more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com